About Alumis Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.alumis.com/
Frequently Asked Questions
What is the 52-week range for ALMS?
The 52-week high is $31.35 and the 52-week low is $3.915.
What is the P/E ratio for ALMS?
The P/E ratio data is currently unavailable.
What is the dividend yield for ALMS?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -102.97%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -6114.62%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.38.
Analyst Recommendation Trends
Wall Street analyst consensus for ALMS over the last few months:
Latest ALMS News
Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alumis Inc. (ALMS) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 7:45 AM EDTCompany ParticipantsMartin Babler - President, CEO...
Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population
Alumis Inc. (NASDAQ:ALMS) reported that the 408-patient Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus did not meet its primary or secondary endpoints in the overall population. Envudeucitinib is an investigational oral inhibitor of tyrosine kinase 2, or TYK2. The primary endpoint was the British Isles Lupus Assessment Group-based Composite Lupus Assessment, […]
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases - Slideshow
2026-09-04. The following slide deck was published by Alumis Inc.
Alumis to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare ConferenceSeptember 8-10, 2026, Boston, MAFireside chat: Tuesday, September 8, 2026 at 11:00 am ET Cantor Global Healthcare Conference September 9-11, 2026
Is Alumis (ALMS) Overvalued After Its 121% One Year Return?
Alumis stock presents a sharp disconnect between recent share price swings and what broad valuation checks suggest. After a very strong 1 year return, the company now screens as expensive on the wider metrics, even after a steep pullback following mixed trial news. Alumis has delivered a 121.2% return over the past year, which puts extra focus on whether the current price already reflects much of the good news investors expect. The recent Phase 2b LUMUS trial setback in lupus, together with...
Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy
In early September 2026, Alumis reported that its Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus failed to meet primary and secondary endpoints in the overall patient population, despite a favorable safety profile over 48 weeks. An important finding was that a prespecified subgroup of patients with a high interferon gene signature showed robust clinical responses, supporting Alumis’ plan to pursue biomarker-driven Phase 3 development and an NDA in...
Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair?
Alumis (ALMS) is back in focus after reporting that envudeucitinib missed primary and secondary endpoints in the Phase 2b LUMUS lupus trial, while a predefined interferon gene signature high subgroup showed stronger clinical responses. That mixed trial readout has gone hand in hand with sharp share price volatility, with a 7 day share price return of down 56.18% and a 30 day share price return of down 60.38%. Alumis still shows a year to date share price return of 15.58% and a 1 year total...
Guggenheim Downgrades Alumis to Neutral
Guggenheim analyst Yatin Suneja downgrades Alumis (NASDAQ:ALMS) from Buy to Neutral.
Alumis (ALMS) Lead Lupus Drug Missed Phase 2b Trial Endpoints
Alumis (NasdaqGS: ALMS) reported that its lead drug envudeucitinib did not meet primary or secondary endpoints in a Phase 2b lupus trial. The company highlighted strong efficacy and safety signals in a genetically defined IFNGS high subgroup of lupus patients within the study. Alumis plans to continue developing envudeucitinib and discuss potential regulatory paths for broader immune mediated indications based on the subgroup data. This update on Alumis shows how targeted drug development...
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-08 | AKKARAJU SRINIVAS | +273,290 | $10.6271 | $2,904,280 |
| 2026-09-08 | AKKARAJU SRINIVAS | +273,291 | $10.6271 | $2,904,291 |
| 2026-09-08 | AKKARAJU SRINIVAS | -48,065 | $10.5484 | $507,009 |
| 2026-09-08 | AKKARAJU SRINIVAS | -48,066 | $10.5484 | $507,019 |
| 2026-09-04 | AKKARAJU SRINIVAS | +220,070 | $11.173 | $2,458,842 |
| 2026-09-04 | AKKARAJU SRINIVAS | +220,070 | $11.173 | $2,458,842 |
| 2026-08-03 | Pangali Sanam | -1,364 | $26.37 | $35,969 |
| 2026-08-03 | Bradley Mark Christopher | -2,572 | $26.37 | $67,824 |
| 2026-08-03 | Drappa Jorn | -2,447 | $26.37 | $64,527 |
| 2026-08-03 | Goldstein David M | -2,596 | $26.37 | $68,457 |
| 2026-08-03 | Schroer John R. | -3,282 | $26.37 | $86,546 |
| 2026-08-03 | Hardiman Roy C. | -2,692 | $26.37 | $70,988 |
| 2026-07-06 | Pangali Sanam | -5,000 | - | - |
| 2026-07-06 | Pangali Sanam | -5,000 | $28 | $140,000 |
| 2026-07-06 | Pangali Sanam | +5,000 | $5.06 | $25,300 |
| 2026-06-30 | TETRAULT LYNN A. | +15,528 | - | - |
| 2026-06-30 | TETRAULT LYNN A. | +3,553 | - | - |
| 2026-06-30 | Srivastava Sapna | +15,528 | - | - |
| 2026-06-30 | Srivastava Sapna | +3,553 | - | - |
| 2026-06-30 | Yao Zhengbin | +15,528 | - | - |
| 2026-06-30 | Yao Zhengbin | +3,553 | - | - |
| 2026-06-30 | Machado Patrick | +15,528 | - | - |
| 2026-06-30 | Machado Patrick | +3,553 | - | - |
| 2026-06-30 | AKKARAJU SRINIVAS | +15,528 | - | - |
| 2026-06-30 | AKKARAJU SRINIVAS | +3,553 | - | - |
| 2026-05-22 | Drappa Jorn | -15,535 | - | - |
| 2026-05-22 | Drappa Jorn | -11,317 | - | - |
| 2026-05-22 | Drappa Jorn | +15,535 | $5.06 | $78,607 |
| 2026-05-22 | Drappa Jorn | +11,317 | $8.84 | $100,042 |
| 2026-04-01 | Foresite Labs, LLC | +680,486 | - | - |
| 2026-04-01 | Foresite Labs, LLC | -1,123,337 | - | - |
| 2026-04-01 | Foresite Labs, LLC | +1,123,337 | - | - |
| 2026-04-01 | Foresite Labs, LLC | -1,176,470 | - | - |
| 2026-04-01 | Foresite Capital Fund V, L.P. | +680,486 | - | - |
| 2026-04-01 | Foresite Capital Fund V, L.P. | -1,123,337 | - | - |
| 2026-04-01 | Foresite Capital Fund V, L.P. | +1,123,337 | - | - |
| 2026-04-01 | Foresite Capital Fund V, L.P. | -1,176,470 | - | - |
| 2026-04-01 | Tananbaum James B. | +680,486 | - | - |
| 2026-04-01 | Tananbaum James B. | -1,123,337 | - | - |
| 2026-04-01 | Tananbaum James B. | +1,123,337 | - | - |
| 2026-04-01 | Tananbaum James B. | -1,176,470 | - | - |
| 2026-01-26 | Pangali Sanam | +186,200 | - | - |
| 2026-01-26 | Bradley Mark Christopher | +190,225 | - | - |
| 2026-01-26 | Drappa Jorn | +221,450 | - | - |
| 2026-01-26 | Goldstein David M | +216,675 | - | - |
| 2026-01-26 | Schroer John R. | +202,225 | - | - |
| 2026-01-26 | Hardiman Roy C. | +190,875 | - | - |
| 2026-01-26 | Babler Martin | +745,875 | - | - |
| 2026-01-09 | AKKARAJU SRINIVAS | +588,235 | $17 | $9,999,995 |
| 2026-01-08 | Foresite Labs, LLC | +294,117 | $17 | $4,999,989 |
| 2026-01-08 | Foresite Labs, LLC | +117,647 | $17 | $1,999,999 |
| 2026-01-08 | Foresite Capital Fund V, L.P. | +294,117 | $17 | $4,999,989 |
| 2026-01-08 | Foresite Capital Fund V, L.P. | +117,647 | $17 | $1,999,999 |
| 2026-01-08 | Tananbaum James B. | +294,117 | $17 | $4,999,989 |
| 2026-01-08 | Tananbaum James B. | +117,647 | $17 | $1,999,999 |
| 2025-12-05 | AKKARAJU SRINIVAS | +51,380 | $10.73 | $551,307 |
| 2025-12-05 | AKKARAJU SRINIVAS | +70,028 | $10.01 | $700,980 |
| 2025-12-05 | AKKARAJU SRINIVAS | +64,969 | $8.95 | $581,473 |
| 2025-12-04 | AKKARAJU SRINIVAS | +66,027 | $8.18 | $540,101 |
| 2025-12-03 | AKKARAJU SRINIVAS | +100,000 | $7.75 | $775,000 |
| 2025-12-02 | AKKARAJU SRINIVAS | +96,000 | $7.55 | $724,800 |
| 2025-12-01 | AKKARAJU SRINIVAS | +86,350 | $7.46 | $644,171 |
| 2025-11-28 | AKKARAJU SRINIVAS | +38,702 | $7.64 | $295,683 |
| 2025-11-26 | AKKARAJU SRINIVAS | +48,537 | $7.64 | $370,823 |
| 2025-11-21 | Foresite Labs, LLC | +72,212 | $7.38 | $532,925 |
| 2025-11-21 | Foresite Capital Fund V, L.P. | +72,212 | $7.38 | $532,925 |
| 2025-11-21 | Tananbaum James B. | +72,212 | $7.38 | $532,925 |
| 2025-11-20 | AKKARAJU SRINIVAS | +125,743 | $7.2 | $905,350 |
| 2025-11-19 | Foresite Labs, LLC | +190,500 | $6.56 | $1,249,680 |
| 2025-11-19 | Foresite Capital Fund V, L.P. | +190,500 | $6.56 | $1,249,680 |
| 2025-11-19 | Tananbaum James B. | +190,500 | $6.56 | $1,249,680 |
| 2025-11-19 | AKKARAJU SRINIVAS | +137,772 | $6.56 | $903,784 |
| 2025-11-18 | Foresite Labs, LLC | +117,374 | $6.19 | $726,545 |
| 2025-11-18 | Foresite Capital Fund V, L.P. | +117,374 | $6.19 | $726,545 |
| 2025-11-18 | Tananbaum James B. | +117,374 | $6.19 | $726,545 |
| 2025-11-18 | AKKARAJU SRINIVAS | +102,652 | $6.05 | $621,045 |
| 2025-11-17 | Foresite Labs, LLC | +150,000 | $5.59 | $838,500 |
| 2025-11-17 | Foresite Labs, LLC | +50,000 | $5.6 | $280,000 |
| 2025-11-17 | Foresite Capital Fund V, L.P. | +150,000 | $5.59 | $838,500 |
| 2025-11-17 | Foresite Capital Fund V, L.P. | +50,000 | $5.6 | $280,000 |
| 2025-11-17 | Tananbaum James B. | +150,000 | $5.59 | $838,500 |
| 2025-11-17 | Tananbaum James B. | +50,000 | $5.6 | $280,000 |
| 2025-11-17 | AKKARAJU SRINIVAS | +914 | $5.51 | $5,036 |
| 2025-11-13 | AKKARAJU SRINIVAS | +276,179 | $5.25 | $1,449,940 |